			Home About us Contact

Retrospective Follow-up Study (retrospective + follow-up_study)

Distribution by Scientific Domains

Medical Sciences	100%

Selected Abstracts

Clinical Experience of TiUniteÔ Implants: A 5-year Cross-Sectional, Retrospective Follow-Up Study

CLINICAL IMPLANT DENTISTRY AND RELATED RESEARCH, Issue 2010
Bertil Friberg DDS
ABSTRACT Background: Little is known of the long-term clinical and radiographic performance of moderately rough surface implants. Purpose: The aim of the present retrospective investigation was to study two pioneer cohorts of patients, that is, the first patients to receive Brånemark System® implants with a moderately rough surface (TiUniteÔ, Nobel Biocare AB, Göteborg, Sweden) at the present clinic. TiUnite implants were inserted either in compromised bone sites in a mixed-mouth concept together with turned implants or used solely. Patients were followed up over a period of 5 years with regard to implant survival and the marginal bone response. Materials and Methods: Patients who received both implant types (mixed group) comprised 41 subjects, and the second group (TiUnite group) comprised 70 subjects. A total of 110 turned and 68 TiUnite implants were placed in the mixed group, and 212 TiUnite implants in the TiUnite group. Follow-up radiographs were obtained at prosthesis placement and at the 1- and 5-year check-ups, and examined by independent observers. Results: One turned (0.9%) and two TiUnite (2.9%) implants failed in the mixed group, and three implants (1.6%) failed in the TiUnite group, indicating no significant differences between surfaces or groups (p < .05). The mean marginal bone loss at 5 years was 0.6 mm to 0.8 mm, also indicating no significant differences for the two implant types tested in the mixed group. Conclusions: Cumulative survival rates for the two implant surfaces were favorable at 5 years, and the marginal bone loss was low and similar for both implant surfaces. [source]

Seronegative myasthenia gravis: disease severity and prognosis

EUROPEAN JOURNAL OF NEUROLOGY, Issue 6 2005
F. Romi
Around 10,20% of myasthenia gravis (MG) patients do not have acetylcholine receptor (AChR) antibodies (seronegative), of whom some have antibodies to a membrane-linked muscle specific kinase (MuSK). To examine MG severity and long-term prognosis in seronegative MG compared with seropositive MG, and to look specifically at anti-AChR antibody negative and anti-MuSK antibody negative patients. Seventeen consecutive seronegative non-thymomatous MG patients and 34 age and sex matched contemporary seropositive non-thymomatous MG controls were included in a retrospective follow-up study for a total period of 40 years. Clinical criteria were assessed each year, and muscle antibodies were assayed. There was no difference in MG severity between seronegative and seropositive MG. However, when thymectomized patients were excluded from the study at the year of thymectomy, seropositive MG patients had more severe course than seronegative (P < 0.001). One seropositive patient died from MG related respiratory insufficiency. The need for thymectomy in seronegative MG was lower than in seropositive MG. None of the seronegative patients had MuSK antibodies. This study shows that the presence of AChR antibodies in MG patients correlates with a more severe MG. With proper treatment, especially early thymectomy for seropositive MG, the outcome and long-term prognosis is good in patients with and without AChR antibodies. [source]

Selective serotonin reuptake inhibitor-induced urinary incontinence

PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, Issue 4 2002
K. L. L. Movig
Abstract Purpose Irrespective of its cause, urinary incontinence is a medical condition seriously affecting quality of life and is increasingly recognized. In this study, we examined the association between the use of selective serotonin reuptake inhibitors (SSRIs) and urinary incontinence. Methods A retrospective follow-up study among starters with an SSRI was performed to estimate the relative and absolute risk for urinary incontinence associated with SSRI use. Data came from the PHARMO database, which includes information on drug dispensing for approximately 450,000 residents living in eight Dutch cities. All patients initially using an SSRI between 1994 and 1998 were selected. The frequency measures for urinary incontinence were estimated by using prescription sequence analysis, where initiation of spasmolytic drugs or absorbent products was used as a measure for urinary incontinence. Besides crude incidence density calculations, Andersen,Gill's model was used in order to control for possible confounding factors and time varying covariates. Results A total of 13,531 were identified as first time users of an SSRI. Compared to non-exposure, the incidence density ratio for urinary incontinence during SSRI exposure was 1.75 (95% CI 1.56,1.97). Overall, compared to baseline, SSRI use caused 14 extra cases of urinary incontinence per 1000 patients treated per year; the elderly were more at risk resulting in 60 extra cases per 1000 patients per year. The adjusted relative risk for urinary incontinence due to SSRI use was 1.61 (95% CI 1.42,1.82); the risk for sertraline users was 2.76; 95% CI 1.47,5.21. Conclusions Exposure to SSRIs is associated with an increased risk for developing urinary incontinence, which can be explaned pharmacologically. Approximately 15 out of 1000 patients treated per year with an SSRI developed urinary incontinence. The elderly and users of sertraline are at the highest risk. Copyright © 2002 John Wiley & Sons, Ltd. [source]

Impact of weekend admissions on quality of care and outcomes in patients with acute myeloid leukemia,

CANCER, Issue 15 2010
Nelli Bejanyan MD
Abstract BACKGROUND: Hospital services are expectantly reduced over the weekend, which may result in a delay in treatment or in obtainment of medical procedures. The authors investigated quality of care and clinical outcomes of newly diagnosed acute myeloid leukemia (AML) patients who were hospitalized on weekends versus weekdays and treated with induction chemotherapy. METHODS: This retrospective follow-up study involved 422 AML patients treated with cytarabine-based induction chemotherapy at Cleveland Clinic from 1994-2008. Quality outcome measures included time to triple-lumen catheter (TLC) placement, time to induction chemotherapy, length of stay (LOS), early death (within 15 days of chemotherapy), and 30-day mortality. These were tested for the association with known predictors of AML survival and etiology by the methods of linear, categorical, and survival analyses. RESULTS: Twenty-three percent of all admissions (n = 422) occurred over the weekend (n = 103). Compared with younger (aged <60 years) patients, older patients had higher 30-day mortality (P = .003), early death (P = .025), and time to induction rates (P = .02), but lower complete remission (P = .001) and overall survival (OS) rates (P < .0001). In univariate analyses, time to TLC was delayed for weekend admissions (P < .01). Weekend admissions had lower early mortality (P = .04) and 30-day mortality (P = .02). In multivariate analysis, only time to TLC remained significantly longer for weekend admissions (P < .001). CONCLUSIONS: Weekend admissions significantly delayed placement of TLC without affecting other quality parameters or patient survival. This is likely because of immediate initiation of peripheral chemotherapy with cytarabine even before the placement of TLC for infusion of anthracyclines. Cancer 2010. © 2010 American Cancer Society. [source]